Fig. 3. Selectivity of NSAIDs for ABCC1.

A: H69AR and the parental H69 cells were treated with doxorubicin in the presence of the IC₂₀ of either sulindac sulfide or indomethacin. The doses of NSAIDs used were 5 μmol/L for sulindac sulfide and 10 μmol/L for indomethacin. B: The ABCB1 expressing uterine sarcoma cell line MES-SA/DX5 was treated with doxorubicin and either 10 μmol/L sulindac sulfide or 30 μmol/L cyclosporin A. C: The ability of sulindac sulfide to sensitize cells to a structurally distinct cytotoxic agent, vincristine, was tested in Jurkat cells expressing ABCC1. Cells were treated with sulindac sulfide alone (squares) to determine the toxicity of sulindac sulfide alone in these cells. The ability of sulindac sulfide (D) or cyclosporin A (E) to sensitize cells to growth inhibition by daunorubicin was determined in Jurkat cells expressing ABCB1. Columns represent the mean of triplicate determinations while bars indicate standard deviation. *P<0.05; **P<0.01, versus the control group.